ストックスクリーナーアプリを入手
7.41
3.26%
-0.25
プレマーケット:
7.01
-0.40
-5.40%
前日終値:
$7.66
開ける：
$7.66
24時間の取引高:
122.76K
Relative Volume:
1.11
時価総額：
$403.16M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-3.01%
1か月 パフォーマンス:
-15.99%
6か月 パフォーマンス:
-40.72%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$7.24
$7.74
1週間の範囲:
$7.24
$7.89
52週間の値動き範囲:
$6.75
$13.50
Alumis Inc Stock (ALMS) Company Profile
ALMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
7.41 | 403.16M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2024-10-17 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 開始されました | Guggenheim | Buy |
| 2024-07-23 | 開始されました | Leerink Partners | Outperform |
| 2024-07-23 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Alumis Inc (ALMS) 最新ニュース
How To Trade (ALMS) - Stock Traders Daily
JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Where are the Opportunities in (ALMS) - Stock Traders Daily
Barclays PLC Has $230,000 Holdings in Bel Fuse Inc. (NASDAQ:BELFA) - Defense World
Principal Financial Group Inc. Invests $289,000 in iShares MBS ETF (NASDAQ:MBB) - Defense World
Jane Street Group LLC Grows Stock Position in Pangaea Logistics Solutions, Ltd. (NASDAQ:PANL) - Defense World
Alumis’ (ALMS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Geode Capital Management LLC Purchases Shares of 305,680 Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Barclays PLC Buys Shares of 18,360 Alumis Inc. (NASDAQ:ALMS) - Defense World
UWM Holdings Co. (NYSE:UWMC) Shares Bought by Barclays PLC - Defense World
Alumis (NASDAQ:ALMS) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reaffirms Buy rating on Alumis stock following Bristol-Myer's PsA data - Investing.com
Piedmont Lithium Inc. (NASDAQ:PLL) Given Average Recommendation of “Hold” by Analysts - Defense World
State Street Corp Makes New Investment in Alumis Inc. (NASDAQ:ALMS) - Defense World
State Street Corp Purchases Shares of 81,059 Alumis Inc. (NASDAQ:ALMS) - MarketBeat
hedge funds investors of Alumis Inc. (NASDAQ:ALMS) must be disappointed after last week's 10% drop - Simply Wall St
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Alumis Inc. (NASDAQ:ALMS) Receives Average Rating of “Buy” from Brokerages - Defense World
Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS), - Yahoo Finance
Stifel Financial Corp Invests $931,000 in Alumis Inc. (NASDAQ:ALMS) - Defense World
Stifel Financial Corp Buys New Holdings in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis’ (ALMS) “Buy” Rating Reiterated at HC Wainwright - Defense World
BNP Paribas Financial Markets Buys New Holdings in Alumis Inc. (NASDAQ:ALMS) - Defense World
Alumis reports positive outcomes from Phase I trial of TYK2 inhibitor - Yahoo! Voices
Alumis (NASDAQ:ALMS) Given "Buy" Rating at HC Wainwright - MarketBeat
Alumis reports promising Phase 1 trial results for MS drug - Investing.com
Alumis reports promising Phase 1 trial results for MS drug By Investing.com - Investing.com South Africa
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 - The Manila Times
Alumis Reports Breakthrough Clinical Data: TYK2 Drug Shows Strong Brain Penetration in Phase 1 Trial - StockTitan
Charles Schwab Investment Management Inc. Takes $1.16 Million Position in Alumis Inc. (NASDAQ:ALMS) - Defense World
Charles Schwab Investment Management Inc. Invests $1.16 Million in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc.’s (NASDAQ:ALMS) Lock-Up Period Set To Expire on December 25th - Defense World
Alumis Inc.'s (NASDAQ:ALMS) Lock-Up Period Will Expire on December 25th - MarketBeat
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Pre-market Movers: LOOP, RPTX, CADL, INO, ISPC… - RTTNews
(ALMS) Technical Data - Stock Traders Daily
Alumis Inc. (NASDAQ:ALMS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Samsara BioCapital LLC Acquires Shares of 3,266,498 Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Quantisnow
How the (ALMS) price action is used to our Advantage - Stock Traders Daily
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow
Ally Bridge Group NY LLC Cuts Stock Holdings in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis: A Best-In-Class TYK2 Inhibitor (NASDAQ:ALMS) - Seeking Alpha
Alumis updates clinical trial dates for lupus study By Investing.com - Investing.com Australia
Alumis updates clinical trial dates for lupus study - Investing.com
Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs - MSN
Protagonist, J&J’s oral IL-23 psoriasis data strong (but short) - BioWorld Online
What is HC Wainwright's Forecast for Alumis FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Weak Estimate for Alumis FY2024 Earnings - MarketBeat
HC Wainwright Lowers Alumis (NASDAQ:ALMS) Price Target to $26.00 - Defense World
Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 - The Manila Times
Alumis Inc (ALMS) 財務データ
Alumis Inc (ALMS) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):